Tue, Sep 16, 2014, 6:26 AM EDT - U.S. Markets open in 3 hrs 4 mins

Recent

% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

racavalli 186 posts  |  Last Activity: Sep 14, 2014 9:56 PM Member since: Jul 31, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Ampio's pipeline is filled with blockbusters and they are all in pivotal or final stages of final trials and ready for BLA, NDA and FDA approvals.

    AMPE will be bought out very soon because they are extremely undervalued and have immense value bot to mention almost $100 million in cash.

    Hopefully JNJ strikes first.

    Sentiment: Strong Buy

  • Reply to

    What Price Will the Shorts Pay To Cover?

    by racavalli Aug 14, 2014 11:21 AM
    racavalli racavalli Aug 14, 2014 1:07 PM Flag

    you can disagree forever but that doesn't alter the FACT that NASDAQ just reported there are over 6.4 million shares short in AMPE and that it will take over 11 days for them to cover based on average volume.

    More power to you if you think you know more than NASDAQ.

    If you really believe that Ampion results are "mediocre" as you call them, then you haven't read the abundant data from many credible third party sources, you are on the wrong board, or are short . . . or perhaps just another whiney, negative and depressed person looking for attention.

    Sentiment: Strong Buy

  • Nasdaq reported 6.4 million shares short and over 11 days to cover.

    There has not been even significant enough trading volume to cover these short positions meaning they are still short.

    We know the final results for the final pivotal trial to clear the way for BLA filing and FDA approval are due out in less that one week.

    Right . . . less than 5 trading sessions. Could be today. Could be tomorrow. Could be Monday.

    Previous trial results have been very strong. Even the FDA called Ampion results "ROBUST".

    And adverse side effects are one o the biggest risks in trial failures. AMPION HAS NONE!

    The big question today is . . . What price will the short have to pay to cover?

    Sentiment: Strong Buy

  • The last FDA comments about Ampion in the Spring Trail results were that Ampion data was "Robust". This was a repeat of the earlier 100 patient phase II trial. These results will be spectacular AGAIN just like before.

    One of the biggest risks for any drug is the side effects and Ampion has CLEARLY DEMONSTRATED IN ALL PREVIOUS TRIALS THAT THERE ARE NO ADVERSE SIDE EFFECTS.

    Latest short interest reports 6.4 million and that it will take over 11 days to cover.

    There has not been enough trading volume to indicate they have covered so it is clear that they are still short.

    With news due Friday or Monday or Tuesday, the shorts are clearly trapped.

    What price do you think they will have to pay?

    Sentiment: Strong Buy

  • Reply to

    lockup

    by billwilliams836 Aug 13, 2014 6:28 PM
    racavalli racavalli Aug 13, 2014 6:58 PM Flag

    That's a REALLY DUMB QUESTION that sounds very much like you are trying to get shareholders concerned about selling. You are way too obvious and should go hawk a different company where you can get away with your nonsense.

    If you had ANY common sense at all, you would know without question that Macaluso, Clift and Bar-Or are not potential sellers for a very long time and only at very high prices if at all. After all this effort and hard work and knowing what they really have, do you really think they would ever entertain selling in the next few years?

    Of course not!

    You got a little too transparent with this question BILL!!!

    It's time for you to go away with your passive aggressive underlying sneaky comments that speak out of both sides of your mouth.

    You're not as clever as you give yourself credit for and many on this board are wise to your negatively posed comments and intentions.

    If you did your homework you would know that both Macaluso and Bar-Or both put their shares in trusts last year where they are safer and shielded with an additional layer of protection from any potential litigants.

    Sentiment: Strong Buy

  • Let's hope the shorts sell much more now so the squeeze will be even greater!

    Sentiment: Strong Buy

  • NASDAQ reports 6.4 million short and more than 11 days of trading to cover.

    Ampion Final Trial news is due out this week or early next week.

    Not enough time for shorts to cover.

    What happens when everybody is a buyer?

    Expect price to advance every day from now and huge spikes on news.

    Since institutions have largely ignored Ampio, it's likely they will start buying after the news which will keep upward buying pressure on the stock for several sessions after news hits.

    Tic . . . Toc . . . Tic . . . Toc

    Sentiment: Strong Buy

  • BioLargo has a revolutionary water treatment technology that is one of the most remarkable technologies in the world and that comes at a time when water is the single biggest problem on our planet.

    A little research clearly shows the immense global problem with droughts, water shortages, and polluted water . . . and the AOS Filter that is an electro-chemical reactor that has been shown by the University of Alberta to decontaminate actual contaminated water from oil recovery field operations in seconds versus hours and at 1/20th of the cost of the closest competing technology. The AOS Filter will change EVERY segment of the $360 billion water treatment industry: Fracking, Oil Sands recovery, refineries, mining, agriculture, municipal water systems, industrial use, and any contaminated water.

    I've been in the markets since 1965 and I can guarantee you that with a story this big, you haven't even begun to see any pumping yet. This is the biggest story on Wall Street and it has not gotten out yet but is on the verge.

    Hang on because this one is going to be enormous.

    Sentiment: Strong Buy

  • Reply to

    The Game Plan....

    by superforce_57 Aug 9, 2014 6:58 PM
    racavalli racavalli Aug 10, 2014 11:14 AM Flag

    The past 40 years of history in the market shows that the vast majority of biotech stocks rise dramatically BEFORE FDA approval and typically over the 12 months before the approval.

    When FDA approval is announced, shares usually spike to upward to new highs for one day on the news and then consolidate for lengthy periods until more news of development or of other drugs is announced.

    Ampio should be no different, but it is fair to expect multiple rallies due to their growing pipeline that could easily fool traders planning on safe-bet short sales.

    As far as money goes, with almost $100 million in cash, Ampio has more than adequate sums and will definitely not have any difficulty raising additional cash if by some chance it is needed. Even if the market craters . . . and nobody can make that prediction with any level of comfort.

    Sentiment: Strong Buy

  • racavalli racavalli Aug 9, 2014 9:46 PM Flag

    This AOS technology is going to revolutionize water treatment and make clean and safe water abundant worldwide.

    Sentiment: Strong Buy

  • I've been researching all the various water technologies to decontaminate water and the AOS Filter is the ONLY one that works better, faster and cheaper than anything else.

    We know that the University of Alberta has already validated it twice and proven that it works in seconds versus hours and uses less than 1/20th of the energy of the closest competitor. If this was not true, the University would have sought a cease and desist long ago.

    I think we are going to hear some major announcements in the coming months that will spike shares to $3 or $4 and much higher as investors learn about BioLargo.

    Contaminated water is a HUGE problem and the AOS Filter is the BEST solution.

    Sentiment: Strong Buy

  • Reply to

    Stock Scam Research

    by tiahamberglhk Aug 5, 2014 3:39 PM
    racavalli racavalli Aug 6, 2014 1:43 AM Flag

    BEWARE

    this posting from tiahamberglhk is a scam to try to get you to sell your shares cheap before prices take off

    Sentiment: Strong Buy

  • racavalli racavalli Aug 5, 2014 7:05 PM Flag

    sending you email

    you might want to check your spam box

    Sentiment: Strong Buy

  • Just read the press releases and run the numbers for yourself.

    Millennium has one of the strongest growth curves I've ever seen and revenues are due to begin their dramatic rise by the end of this year or sooner.

    The MHCC model is unique, effective, and will mold Millennium into a very large healthcare company.

    Sentiment: Strong Buy

  • Reply to

    someone

    by darilla911 Aug 5, 2014 2:05 PM
    racavalli racavalli Aug 5, 2014 3:25 PM Flag

    Millennium HealthCare is a VERY STRONG BUY because their growth curve is one of the most exponential in the entire industry and all the pieces are in place for massive revenue growth beginning this year.

    Investors should read all the press releases to understand the numbers.

    It won't take long for investors to figure this out.

    Sentiment: Strong Buy

  • Reply to

    Still 6 million short

    by getshorty20700 Aug 5, 2014 1:10 PM
    racavalli racavalli Aug 5, 2014 3:14 PM Flag

    traders should not care if they make money in log positions or short positions.

    shorts are extremely short term and are in and out quickly unless it is a hedged position

    watch the short interest continue to rise as the price and volume rises

    Sentiment: Strong Buy

  • Reply to

    Why Citicorp $21 Price Target Just Tripled

    by racavalli Aug 5, 2014 11:36 AM
    racavalli racavalli Aug 5, 2014 12:09 PM Flag

    The big announcement of the Ampion final trial that sets up FDA approval is due any day between now and the next two weeks.

    This company's pipeline is so active that it would not be surprising to see unexpected news at any time.

    Sentiment: Strong Buy

  • Citicorp initiated AMPE coverage with a $21 Price Target that was based on a single injection of Ampion and with Peak Penetration of only 13% of the market.

    Today's results were not only SPECTACULAR, but were based on THREE injections.

    These results tend to portend a much larger share of the market than 13%

    TRIPLE THE INJECTIONS AND TRIPLE THE PROJECTED REVENUES FROM AMPION.

    Then there is cartilage regeneration.

    Then there are Ampion for other joints besides knees.

    Then there is Ampion for Crohn's.

    Then there is Ampion for COPD

    Then there is Ampion for allergies

    Then there is Optina for eyes.

    Then there is Optina for kidneys.

    Then there is Zertane and Zertane ED

    Then there is NCE001 , a new class of cancer drug that is a phosphatase activator

    Then there is ORP

    Then there is almost $100 million in CASH

    Then there is NO DEBT.

    This is why Citicorp has been repeatedly saying that Ampio is exceptionally undervalued.

    Sentiment: Strong Buy

  • racavalli racavalli Aug 4, 2014 8:32 PM Flag

    Andrew,

    I know management well and they are for real and they have more talent and integrity that the market gives them credit for. They have not sold a single share and are not in Ampio for a short term quick profit.

    Their drugs are exceptional. It appears they can help millions of people suffering from osteoarthritis, DME, kidney failure and a host of other indications that I believe will be proven through clinical trials.

    It's also very important to understand that Ampio is developing drugs with no serious adverse side effects that you unfortunately see with almost every other drug on the market.

    I believe you will see them develop a long list of drugs for many indications and will be instrumental in actually helping people with socially responsible drugs unlike today's irresponsible pharma industry that will do anything for a buck at the expense of the patients.

    Ampio's shares are highly undervalued for many reasons, but I believe that is about to begin to change in the next few days as we draw closer to results from the final trial for Ampion.

    I believe Ampio is destined to become a very large company . . . unless they are bought out soon by big pharma which is a real possibility now since shares are so cheap.

    Stick it out and you will see share prices begin to explode in the next few days weeks and months.

    This is going to be a tremendous success story for those who stay strong and just hold. Buy as much as you can afford and HOLD for the long term and watch your investment soar.

    There are many short players who frequently bash Ampio. Just ignore them because they are just trying to sucker shareholders into selling cheap so they can profit.

    You are almost there.

    Sentiment: Strong Buy

  • Google "BIOLARGO AOS FILTER ON VIMEO"

    Sentiment: Strong Buy

AMPE
3.65+0.05(+1.39%)Sep 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT